PubMed
MK-677, an orally active growth hormone secretagogue: effects on body composition
Murphy et al., 1998
Ibutamoren
Oral ghrelin receptor agonist used in GH-axis research.
Trend index
Overview
Oral ghrelin receptor agonist used in GH-axis research.
Community
Positive 98% · Neutral 2% · Negative 0%
Median: 2000+ mcg · Most common: 2000+ mcg
Among repeat reporters, 91% said they felt similar to their last entry, 9% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 156 days · Based on 22 repeat reporters
Research
PubMed
Murphy et al., 1998
PubMed
Nass et al., 2008
Help
This page summarizes 24 anonymized self-reports from PeptIQ users who track MK-677, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. MK-677 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests MK-677 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceMK-677 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified MK-677 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of MK-677 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on MK-677, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source